<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028600</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-100001</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CALGB-100001</secondary_id>
    <secondary_id>CDR0000069109</secondary_id>
    <nct_id>NCT00028600</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor
      may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor
      cells. The donated stem cells may also help destroy any remaining cancer cells
      (graft-versus-tumor effect).

      PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant
      followed by donor peripheral stem cell transplant works in treating patients with multiple
      myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether autologous peripheral blood stem cell transplantation (PBSCT) followed
           by non-myeloablative allogeneic PBSCT is associated with no more than 20%
           treatment-related mortality rates at 6 months in patients with multiple myeloma.

        -  Determine the response rate of patients treated with this regimen.

        -  Determine the percent donor chimerism in patients treated with this regimen.

        -  Determine the rate of graft-vs-host disease in patients treated with this regimen.

        -  Determine the toxic effects of this regimen in these patients.

        -  Determine the disease-free and overall survival of patients treated with this regimen.

        -  Determine whether abnormal cytogenetics at presentation correlate with poor response in
           patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive cyclophosphamide IV over 1-2 hours on day 1 and filgrastim (G-CSF)
      subcutaneously (SC) beginning on day 5 and continuing until peripheral blood stem cell (PBSC)
      collection is complete.

      Approximately 2-4 weeks after PBSC collection, patients receive melphalan IV over 15-30
      minutes on day -2. Patients then undergo autologous PBSC transplantation (PBSCT) on day 0.
      Patients receive G-CSF SC beginning on day 5 and continuing until blood counts recover.

      Approximately 2-4 months after autologous PBSCT, patients receive fludarabine IV over 30
      minutes on days -7 to -3 and cyclophosphamide IV over 1 hour on days -4 to -3. Patients
      undergo allogeneic PBSCT on day 0. Patients receive G-CSF SC beginning on day 7 and
      continuing until blood counts recover.

      Patients receive graft-vs-host disease (GVHD) prophylaxis comprising oral tacrolimus twice
      daily on days -1 to 90 followed by a taper on days 91-150 and methotrexate IV on days 1, 3,
      and 6.

      After day 120, patients with stable or progressive disease and no evidence of active GVHD may
      receive donor lymphocyte infusion (DLI) over 2 hours. Patients may receive up to 3 DLIs every
      8 weeks.

      Patients are followed every 3 months for 3 years, every 6 months for 5 years, and then
      annually for 15 years.

      PROJECTED ACCRUAL: A maximum of 63 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Completion Rate</measure>
    <time_frame>post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respone Rate</measure>
    <time_frame>2-4 wks prior, and 3,6 mon then q 3 mon for 3 yrs, post allo transpl, then q 6 mon for max 15 yrs from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism Rate</measure>
    <time_frame>1,2,3,4, &amp; 6 mon post allo transpl, &amp; 100 d post DLI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD Incidence</measure>
    <time_frame>post allo transpl, &amp; pre &amp; post DLI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall and disease free survival will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of cytogenetics and response</measure>
    <time_frame>6, 12 mon then q 1 yr for 3 yrs post allo transpl</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC &gt;= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC &gt; 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD34+ cells</intervention_name>
    <description>2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>200mg/sq m IV infusion over 15-30 min D 2 auto transpl</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>5mg/sq m/d IV infusion D 1,3,&amp; 6: allo transpl</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150</description>
    <arm_group_label>Autologous + Allogeneic Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of active multiple myeloma that requires treatment

               -  Durie-Salmon stage I, II, and III

          -  No more than 1 progression after initial therapy

          -  Must have HLA-identical sibling donor (6/6) by serologic typing (A, B, DR)

               -  No syngeneic donors

          -  Must also be enrolled on protocol CLB-8461 (Cytogenetic Studies in Acute Leukemia)

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 65

        Performance status:

          -  NCI CTC 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 500/mm^3

          -  Platelet count greater than 50,000/mm^3

        Hepatic:

          -  Bilirubin less than 2 mg/dL

          -  AST less than 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase less than 3 times ULN

        Renal:

          -  Creatinine less than 2 mg/dL

          -  Creatinine clearance greater than 40 mL/min

        Cardiovascular:

          -  LVEF at least 30% by MUGA scan

        Pulmonary:

          -  DLCO greater than 40% of predicted

          -  No symptomatic pulmonary disease

        Other:

          -  HIV negative

          -  No uncontrolled diabetes mellitus

          -  No active serious infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy

          -  Prior alkylating-agent therapy allowed if no more than 12 months duration

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

        Surgery:

          -  At least 4 weeks since prior surgery

        Other:

          -  All prior therapy no more than 18 months duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C. Anderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tunnell Cancer Center at Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Program at Union Hospital</name>
      <address>
        <city>Elkton MD</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - Saint Louis</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-1791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

